Pacific Biosciences of California, Inc. engages in the design, development, and manufacture of sequencing systems to help scientists resolve genetically complex problems. Based on the company’s single molecule, real-time (SMRT) Sequencing technology, its products enable: de novo genome assembly to finish genomes to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. The company’s technology combines very high consensus accuracy and long read lengths with the ability to detect real-time kinetic information. The company’s customers and its scientific collaborators have published various peer-reviewed articles in journals, including Nature, Science, Cell, PNAS and The New England Journal of Medicine highlighting the power and applications of SMRT sequencing in projects, such as finishing genomes, structural variation discovery, isoform transcriptome characterization, rare mutation discovery and the identification of chemical modifications of DNA related to virulence and pathogenicity. PacBio Systems The PacBio RS II and Sequel Systems conduct, monitor, and analyze biochemical sequencing reactions. The PacBio RS II and Sequel instruments are integrated units that include optics, automated liquid handling, a touchscreen control interface and computational hardware and software. Each instrument’s optics monitor the ZMWs in a SMRT Cell in real time. The computational hardware and software in each instrument is responsible for processing the sequencing data produced by the SMRT Cells. Consumables Customers must purchase proprietary consumable products to run either the PacBio RS II System or Sequel System. The company’s consumable products include its proprietary SMRT Cells and reagent kits. One SMRT Cell is consumed per sequencing reaction, and scientists could choose the number of SMRT Cells they use per experiment. For the PacBio RS II instrument, eight SMRT Cells containing approximately 150,000 ZMWs each are individually and hermetically sealed then packaged together into a streamlined 8Pac format. Sequel System customers purchase a similarly packaged, four SMRT Cell format with approximately 1 million ZMWs each. The company offers various reagent kits, each designed to address a specific step in the workflow. A template preparation kit is used to convert DNA into SMRTbell double-stranded DNA library formats and includes typical molecular biology reagents, such as ligase, buffers and exonucleases. Its binding kits include its modified DNA polymerase, and are used to bind SMRTbell libraries to the polymerase in preparation for sequencing. Its sequencing kits contain reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. Strategy The key elements of the company’s strategy are to offer differentiated products based on its proprietary SMRT technology; offer differentiated products based on its proprietary SMRT technology; create a global community of users to enhance informatics capabilities, develop sample preparation solutions, and drive adoption of its products in new application and market areas; leverage SMRT technology and community engagement to expand application capabilities and penetrate new markets; and partner with F. Hoffman-La Roche Ltd to sell to the in vitro diagnostics market. Sales and Marketing The company markets its products through a direct sales force in North America and Europe and primarily through distributors in Asia. Customers The company’s customers use its products for sequencing genomes and transcriptomes across a range of organisms. Its customers include research institutions, commercial laboratories, genome centers, clinical, government and academic institutions, genomics service providers, pharmaceutical companies and agricultural companies. Research and Development The company’s research and development expense incurred was$60.4 million during 2015. Intellectual Property As of December 31, 2015, the company owned or held exclusive licenses to 203 issued U.S. patents, 113 pending U.S. patent applications, 91 granted foreign patents and 85 pending foreign patent applications, including foreign counterparts of the U.S. patent and patent applications. The full term of the issued U.S. patents would expire between 2016 and 2033. Competition The company’s competitors include Illumina Inc. and Thermo Fisher Scientific Inc. History Pacific Biosciences of California, Inc., formerly Nanofluidics, Inc. was incorporated in the state of Delaware in 2000.
pacific biosciences of calif
(PACB:Consolidated Issue Listed on NASDAQ Global Select )
1380 Willow Road
Menlo Park, CA 94025
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for PACB.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact PACIFIC BIOSCIENCES OF CALIF, please visit www.pacb.com. Company data is provided by Capital IQ. Please use this form to report any data issues.